Ferrer Internacional has formally notified the European Medicines Agency of its decision to withdraw the marketing authorisation application (MAA) for Egrifta (tesamorelin) 2mg powder for injection.

The company submitted the MAA for Egrifta to the agency on 31 May 2011, during which time it was under review by the agency’s Committee for Medicinal Products for Human Use (CHMP).

The company had taken the decision to withdraw the application, as the CHMP considers the provided data to be insufficient to conclude on a positive benefit-risk balance.

According to the application, Egrifta was intended to be used for the treatment of excess visceral adipose tissue, defined as a level greater than 130cm² by imaging procedures, in treatment-experienced HIV-infected patients.

According to the European Medicines Agency, the withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage.

The GHRH analog tesamorelin (trade name Egrifta) drug was designed for the treatment of lipodystrophy in HIV patients under highly active antiretroviral therapy, and was approved by the US Food and Drug Administration in November 2010.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.